Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Kaplan
Steven A
SA
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D015982:Bias; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004979:Ethamsylate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009122:Muscle Hypertonia / Q000175:diagnosis / Q000188:drug therapy; D009281:Naphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D008517:Phytotherapy; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy*; D016037:Single-Blind Method; D016896:Treatment Outcome; D001748:Urinary Bladder Neck Obstruction / Q000175:diagnosis / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D004338:Drug Combinations; D009281:Naphthalenes; D010879:Piperazines; D010936:Plant Extracts; D004979:Ethamsylate; C010152:eviprostat; C064357:naftopidil